title: [Inhibition of sanguinarine on S180 subcutaneously implanted tumors in mice].
abstract: OBJECTIVE
  To investigate the inhibition of sanguinarine on S180 sarcoma in mice and the effect of angiogenesis.
  
  
  METHODS
  S180 subcutaneous implanted tumor model mice were randomly divided into six groups: control group, cyclophosphamide (CTX) group, sanguinarine (10, 20 and 40 mg/kg) groups and combination group. The mice were sacrificed on the 10th day to measure the tumor weight and volumes, and caculate the tumor growth inhibition. Histopathology was performed, while immunohistochemistry was applied for assessment of MVD (microvascular density) and the expression of VEGF (vascular endothelial growth factor).
  
  
  RESULTS
  The growth of tumors were significantly inhibited in the treatment groups (CTX group, sanguinarine 20 and 40 mg/kg groups, and combination group). HE staining showed tumor cell atypia and pathologic micosis were lower than that of the control group. Scattered and fusion of the slice necrosis foci were observed in the treatment groups. CTX, sanguinarine (20 and 40 mg/kg) and combination significantly reduced the expression of MVD and VEGF compared with the control group (P < 0.01, P < 0.05).
  
  
  CONCLUSIONS
  Sanguinarine can effectively inhibit the growth of S180 implanted tumors via reducing MVD and the expression of VEGF, which is associated with its anti-angiogenesis.
authors.forename: Xian-hua
authors.initials: XH
authors.lastname: Du
authors.forename: Song
authors.initials: S
authors.lastname: Huang
authors.forename: Hong-rui
authors.initials: HR
authors.lastname: Feng
authors.forename: Lin-lin
authors.initials: LL
authors.lastname: Chen
authors.forename: Sha
authors.initials: S
authors.lastname: Yang
authors.forename: Lin-feng
authors.initials: LF
authors.lastname: Lu
mesh_terms: D000818:Animals; D053119:Benzophenanthridines / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic; D012510:Sarcoma 180 / Q000188:drug therapy*; D047368:Tumor Burden; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D053119:Benzophenanthridines; D007546:Isoquinolines; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; D003520:Cyclophosphamide; C005705:sanguinarine